HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aesthetic Medicine

1,209.961

+5.3430.44%

Number of Gainers:3

Number of Losers:4

Number of Flat:6

PE:- -

High:1,222.114

Open:1,205.485

Low:1,205.485

Close:1,204.618

Volume:28.96M

Turnover:77.06M

Market Cap:200.72B

Float Cap:150.23B

Loading ...

BRIEF-Sihuan Pharma Sees Net Profit Of Not Less Than RMB150 Million For Year

Sihuan Pharmaceutical Issues Positive Profit Alert, Anticipates Revenue Exceeding RMB 25 Billion for Fiscal Year 2025

Sihuan Pharma Sees Net Profit of Not Less Than RMB150 Mln for Year

THOMSON REUTERS

Sihuan Pharma - Expects Revenue of at Least RMB2,500 Mln in FY

THOMSON REUTERS

Sihuan Pharmaceutical Expects Significant Profit Growth for 2025

A Look At 3SBio (SEHK:1530) Valuation After Recent Share Price Strength

Simply Wall St.

Fosun Pharma Unit Gets China Acceptance for Application of Local Anaesthetic

MT Newswires Live

BUZZ-InSilico hits fresh high on partnership deal with China Medical

Insilico Medicine Enters Drug Development Partnership With China Medical System

MT Newswires Live

Insilico Partners with CMS on Multi-Million-Dollar AI-Driven Drug Development for CNS and Autoimmune Disorders

Insilico Medicine Cayman Topco startet Milliarden-Kooperation mit CMS zur Entwicklung von Medikamenten für das zentrale Nervensystem und Autoimmunerkrankungen

Sealand Securities Starts Sihuan Pharmaceutical Holdings Group at Buy

MT Newswires Live

Sisram Medical Showcases Intelligent Aesthetics Innovations at IMCAS World Congress 2026

Hillhouse Increases Stake in Dental Giant, Signaling Confidence in Oral Care Sector

FOSUN PHARMA's Cyclophosphamide Injection Application Accepted for Review

BOCOM International Forecasts Continued Stable Growth for Healthcare Sector This Year, Recommends Seeking Undervalued Stocks

Fosun Pharma's Subsidiary Henlius Enters Licensing Agreement with Eisai for Cancer Treatment

Assessing China Medical System Holdings (SEHK:867) Valuation After CMS D017 Clinical Trial Approval

Simply Wall St.

China Medical System Receives Regulatory Nod to Begin Trials of CMS-D017

MT Newswires Live

CMS (00867) Self-Developed Innovative Drug CMS-D017 Capsule Receives Clinical Trial Approval Notice for Complement-Mediated Kidney Diseases

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1593/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":1209.9609,"timestamp":1770773773878,"preClose":1204.6179,"halted":0,"volume":28957347,"delay":0,"changeRate":0.004435,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":5.343018,"latestTime":"02-11 09:36:13","open":1205.4852,"high":1222.114,"low":1205.4852,"amount":77060041,"amplitude":0.013804,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1770782400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1770773400000,1770782400000],[1770786000000,1770796800000]],"pbRate":1.734286,"peRate":24.977799,"turnoverRate":0.0014,"increases":3,"decrements":4,"flats":6,"marketCap":200721933816,"floatMarketCap":150230759992},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1222.114,"amplitude":0.013804,"preClose":1204.6179,"low":1205.4852,"pbRate":"1.734286","latestPrice":1209.9609,"volume":28957347,"delay":0,"open":1205.4852,"prevYearClose":1094.978,"prevWeekClose":1170.946,"prevMonthClose":1146.099,"prevQuarterClose":1094.978,"fiveDayClose":1159.505,"twentyDayClose":1210.834,"sixtyDayClose":1365.908,"secType":"PLATE","market":"HK","turnoverRate":0.0014,"peRate":24.977799,"marketCap":200721933816,"floatMarketCap":150230759992,"timestamp":1770773773878,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":3,"down":4,"flat":6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610262130","title":"BRIEF-Sihuan Pharma Sees Net Profit Of Not Less Than RMB150 Million For Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2610262130","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610262130?lang=en_us&edition=fundamental","pubTime":"2026-02-10 23:17","pubTimestamp":1770736620,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharma Sees Net Profit Of Not Less Than RMB150 Million For YearFeb 10  - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:SEES NET PROFIT OF NOT LESS THAN RMB150 MILLION FOR YEAREXPECTS REVENUE OF AT LEAST RMB2,500 MILLION IN FYFurther company coverage: 0460.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z60OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1600","BK1191","00460","BK1593"],"gpt_icon":0},{"id":"1192554954","title":"Sihuan Pharmaceutical Issues Positive Profit Alert, Anticipates Revenue Exceeding RMB 25 Billion for Fiscal Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1192554954","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192554954?lang=en_us&edition=fundamental","pubTime":"2026-02-10 23:07","pubTimestamp":1770736068,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical (00460) has announced a positive profit alert. Based on a preliminary assessment of the company's unaudited consolidated management accounts and current information available to...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","00460","BK1191","BK1593","BK1515"],"gpt_icon":0},{"id":"2610629912","title":"Sihuan Pharma Sees Net Profit of Not Less Than RMB150 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2610629912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610629912?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:54","pubTimestamp":1770735272,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z60OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1600","BK1515","BK1593","00460","BK1191"],"gpt_icon":0},{"id":"2610629911","title":"Sihuan Pharma - Expects Revenue of at Least RMB2,500 Mln in FY","url":"https://stock-news.laohu8.com/highlight/detail?id=2610629911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610629911?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:54","pubTimestamp":1770735272,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z60OR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","BK1191","BK1515","00460","BK1600"],"gpt_icon":0},{"id":"2610629949","title":"Sihuan Pharmaceutical Expects Significant Profit Growth for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2610629949","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610629949?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:54","pubTimestamp":1770735252,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. has issued a positive profit alert for the year, indicating a significant improvement in business performance. The company highlighted that its innovative drug business has entered a harvest period, with subsidiaries Xuanzhu Biopharm and Huisheng Biopharm achieving notable year-on-year revenue growth. Sihuan Pharmaceutical also reported a transition from an investment phase to a revenue-generating phase in its innovative drug segment, leading to a marked enhancement in its profit structure. Additionally, the company noted substantial equity appreciation gains following the successful spin-off listing of Xuanzhu Biopharm and multiple rounds of share repurchases, which have strengthened its financial position and driven breakthroughs in profitability.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL137MZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1593","02575","BK1515","BK1600","00460"],"gpt_icon":0},{"id":"2610294629","title":"A Look At 3SBio (SEHK:1530) Valuation After Recent Share Price Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2610294629","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610294629?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:21","pubTimestamp":1770726111,"startTime":"0","endTime":"0","summary":"What recently stood out about 3SBio\n3SBio (SEHK:1530) has caught investor attention after recent share price moves, with a 4.3% gain over the past day and a 6.5% rise over the past week, contrasting with weaker returns over the past month and past 3 months.\nSee our latest analysis for 3SBio.\nStepping back, the 1-day and 7-day share price returns of 4.26% and 6.52% sit against a weaker 30-day and 90-day share price picture. At the same time, the one year total shareholder return of roughly 3x...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/a-look-at-3sbio-sehk1530-valuation-after-recent-share-price","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/a-look-at-3sbio-sehk1530-valuation-after-recent-share-price","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","01530","HK0000165453.HKD","BK1161","BK1583","BK1593"],"gpt_icon":0},{"id":"2610174646","title":"Fosun Pharma Unit Gets China Acceptance for Application of Local Anaesthetic","url":"https://stock-news.laohu8.com/highlight/detail?id=2610174646","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610174646?lang=en_us&edition=fundamental","pubTime":"2026-02-10 18:43","pubTimestamp":1770720239,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  said the drug registration application of Tetracaine Hydrochloride Gel was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The application was submitted by Shanghai Zhaohui Pharmaceutical, a unit of the pharmaceutical firm.The drug is intended to be used as a percutaneous local anaesthetic for the skin prior to venepuncture or venous cannulation.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK0239","BK0183","BK0175","02196","BK1593","BK0096","BK0028","BK0188","BK0012","BK1191","BK0187","BK1515","BK0196","600196"],"gpt_icon":0},{"id":"2610696513","title":"BUZZ-InSilico hits fresh high on partnership deal with China Medical","url":"https://stock-news.laohu8.com/highlight/detail?id=2610696513","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610696513?lang=en_us&edition=fundamental","pubTime":"2026-02-10 10:17","pubTimestamp":1770689824,"startTime":"0","endTime":"0","summary":"BUZZ-InSilico hits fresh high on partnership deal with China Medical.** Shares of InSilico Medicine Cayman TopCo 3696.HK jump 9.9% to HK$73.8, a fresh high since their debut on December 30, 2025** Stock on track for biggest daily gain since February 3; on track for second session of rise** InSilico says it has entered into a strategic partnership with China Medical System 0867.HK on innovative drug development in the fields of central nervous system and autoimmune diseases** Insilico says the two parties will jointly advance the co-development of no fewer than two R&D programs** The company is expected to receive R&D funding support of up to several tens of millions of Hong Kong dollars for each program** Shares of China Medical System slip 2% ** Insilico stock has soared 202% from the HK$24.05 IPO price in nearly 6 weeks** YTD, Insilico shares up 92.5%, Hang Seng Biotech Index .HSBIO up 11.3%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL1N3Z601U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","00867","BK1141","IE00BYV24P56.USD","SG9999015945.SGD","BK1191","IE00BVYPNP33.GBP","SG9999015986.USD","SG9999015952.SGD","BK1593","03696","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","SG9999015978.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2610693787","title":"Insilico Medicine Enters Drug Development Partnership With China Medical System","url":"https://stock-news.laohu8.com/highlight/detail?id=2610693787","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610693787?lang=en_us&edition=fundamental","pubTime":"2026-02-10 09:38","pubTimestamp":1770687485,"startTime":"0","endTime":"0","summary":"Insilico Medicine  said it entered a drug development partnership with China Medical System , according to a Hong Kong bourse filing Tuesday.Under the agreement, the two sides will collaborate to co-develop at least two drugs.Insilico Medicine is expected to receive R&D funding support of up to \"several tens of millions of HKD\" for each program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["8A8.SI","SG9999015945.SGD","IE00BVYPNP33.GBP","SG9999004220.SGD","SG9999015986.USD","SG9999015952.SGD","BK1593","BK1141","03696","BK6079","00867","LU2488822045.USD","IE00BMCWC346.EUR","BK1191","IE00BGHQDM52.EUR","SG9999015978.USD","IE00BYV24P56.USD","IE00BVYPNQ40.USD"],"gpt_icon":0},{"id":"1106267413","title":"Insilico Partners with CMS on Multi-Million-Dollar AI-Driven Drug Development for CNS and Autoimmune Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=1106267413","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106267413?lang=en_us&edition=fundamental","pubTime":"2026-02-10 08:20","pubTimestamp":1770682819,"startTime":"0","endTime":"0","summary":"Insilico (03696) has announced that the group has entered into a strategic drug development collaboration with CMS. Under this partnership, the two companies will engage in a series of AI-enabled...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNP33.GBP","SG9999015986.USD","03696","IE00BMCWC346.EUR","SG9999015952.SGD","BK1593","IE00BYV24P56.USD","BK1141","IE00BVYPNQ40.USD","SG9999004220.SGD","SG9999015978.USD","LU2488822045.USD","00867","SG9999015945.SGD","BK1191","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"2610667618","title":"Insilico Medicine Cayman Topco startet Milliarden-Kooperation mit CMS zur Entwicklung von Medikamenten für das zentrale Nervensystem und Autoimmunerkrankungen","url":"https://stock-news.laohu8.com/highlight/detail?id=2610667618","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610667618?lang=en_us&edition=fundamental","pubTime":"2026-02-10 08:01","pubTimestamp":1770681703,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLbDr1GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQDM52.EUR","00867","IE00BVYPNP33.GBP","SG9999004220.SGD","BK1141","SG9999015952.SGD","BK1191","SG9999015978.USD","LU2488822045.USD","IE00BYV24P56.USD","SG9999015945.SGD","IE00BVYPNQ40.USD","SG9999015986.USD","03696","BK1593","IE00BMCWC346.EUR"],"gpt_icon":0},{"id":"2610343886","title":"Sealand Securities Starts Sihuan Pharmaceutical Holdings Group at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2610343886","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610343886?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:16","pubTimestamp":1770635761,"startTime":"0","endTime":"0","summary":"Sealand Securities Starts Sihuan Pharmaceutical Holdings Group at Buy","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","BK1515","00460","BK1600","BK1191"],"gpt_icon":0},{"id":"2609300563","title":"Sisram Medical Showcases Intelligent Aesthetics Innovations at IMCAS World Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2609300563","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609300563?lang=en_us&edition=fundamental","pubTime":"2026-02-06 16:30","pubTimestamp":1770366616,"startTime":"0","endTime":"0","summary":"Sisram Medical Ltd., through its core subsidiary Alma, participated in the IMCAS World Congress 2026 in Paris from January 29 to 31. At the event, the company highlighted its advancements in intelligent aesthetics, showcasing new clinical evidence on scar management, rejuvenation, and tattoo removal. Sisram featured presentations on multi-technology laser platforms and introduced innovations such as the Alma Hybrid platform for keloid scar management and the Harmony Bio-Boost collagen-stimulating treatment. Company leaders, including CEO Eyal Ben David and Chairman Lior Dayan, took part in scientific sessions and industry forums, reinforcing Sisram’s commitment to evidence-based, personalized aesthetic solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL254rtH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1100","BK1593","00656","BK1230","01696"],"gpt_icon":0},{"id":"1174956619","title":"Hillhouse Increases Stake in Dental Giant, Signaling Confidence in Oral Care Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1174956619","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174956619?lang=en_us&edition=fundamental","pubTime":"2026-02-05 18:50","pubTimestamp":1770288649,"startTime":"0","endTime":"0","summary":"Investment firm Hillhouse Capital is significantly increasing its stake in Hong Kong-listed Modern Dental Group, raising its shareholding from below 1% to approximately 17%. This transaction is...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","03600","BK1583","BK1100"],"gpt_icon":0},{"id":"1103851342","title":"FOSUN PHARMA's Cyclophosphamide Injection Application Accepted for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1103851342","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103851342?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:31","pubTimestamp":1770283892,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) announced that its controlled subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., recently had the drug registration application for Cyclophosphamide Injection accepted by the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0175","BK1593","BK0012","BK0187","BK0188","BK1191","BK0196","02196","BK1515","600196","BK0183","BK0239","BK0060","BK0096"],"gpt_icon":0},{"id":"1132125759","title":"BOCOM International Forecasts Continued Stable Growth for Healthcare Sector This Year, Recommends Seeking Undervalued Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1132125759","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132125759?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:16","pubTimestamp":1770282992,"startTime":"0","endTime":"0","summary":"The Hang Seng Healthcare Index declined 3.3% this week, underperforming the broader market. Since the fourth quarter of last year, the proportion of mainland capital holding pharmaceutical stocks...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","BK1574","BK1161","09939","BK1141","LU2488822045.USD","BK1583","BK1593","HK0000165453.HKD","02595","BK1587","01530","BK1191","BK1588","SG9999014674.SGD","02268","03329","00013","BK1147"],"gpt_icon":0},{"id":"1136411007","title":"Fosun Pharma's Subsidiary Henlius Enters Licensing Agreement with Eisai for Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1136411007","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136411007?lang=en_us&edition=fundamental","pubTime":"2026-02-05 16:57","pubTimestamp":1770281862,"startTime":"0","endTime":"0","summary":"Fosun Pharma's controlled subsidiary Henlius has entered into a licensing agreement with Eisai, granting the latter exclusive rights to develop, manufacture, and commercialize the innovative...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0187","BK1191","BK0196","BK1515","600196","HK0000306701.USD","BK0096","BK0028","BK1593","BK0012","BK0183","BK0239","BK0188","02196","HK0000320223.HKD","HK0000306685.HKD","BK0060","HK0000165453.HKD","BK1161","HK0000320264.USD","02696"],"gpt_icon":0},{"id":"2609340033","title":"Assessing China Medical System Holdings (SEHK:867) Valuation After CMS D017 Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2609340033","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609340033?lang=en_us&edition=fundamental","pubTime":"2026-02-05 11:42","pubTimestamp":1770262952,"startTime":"0","endTime":"0","summary":"China Medical System Holdings (SEHK:867) has secured approval from China's National Medical Products Administration to start clinical trials for CMS-D017, an oral complement factor B inhibitor targeting paroxysmal nocturnal hemoglobinuria.\nSee our latest analysis for China Medical System Holdings.\nTrading at HK$14.58, China Medical System Holdings has seen firm momentum recently, with a 7 day share price return of 4.59%, a 30 day share price return of 7.44%, and a 1 year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1003077747.HKD","BK4588","BK1593","SG9999015978.USD","LU2488822045.USD","LU2637428348.USD","LU2500361329.USD","IE00BVYPNP33.GBP","CMS","SG9999015952.SGD","BK4585","LU2346227817.USD","BK4208","SG9999015986.USD","LU1894683264.USD","LU0738911758.USD","IE00BYV24P56.USD","IE00BMCWC346.EUR","DCF","IE00BVYPNQ40.USD","LU1894683348.USD","LU0661504455.SGD","LU0545039389.USD","LU0553294199.USD","LU0949170772.SGD","SG9999004220.SGD","SG9999015945.SGD","BK1191","00867","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"2608133602","title":"China Medical System Receives Regulatory Nod to Begin Trials of CMS-D017","url":"https://stock-news.laohu8.com/highlight/detail?id=2608133602","media":"MT Newswires Live","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608133602?lang=en_us&edition=fundamental","pubTime":"2026-02-04 12:03","pubTimestamp":1770177832,"startTime":"0","endTime":"0","summary":"China Medical System  received Chinese regulatory approval to begin human trials of CMS-D017, according to a Hong Kong bourse filing Tuesday.The firm plans to evaluate the drug's safety and tolerability in healthy participants in China.The medicine is being developed to treat complement-mediated kidney diseases.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1894683264.USD","00867","BK4208","LU2500361329.USD","SG9999015978.USD","BK4585","SG9999015945.SGD","LU1003077747.HKD","IE00BMCWC346.EUR","LU1894683348.USD","LU0738911758.USD","IE00BGHQDM52.EUR","CMS","IE00BYV24P56.USD","SG9999004220.SGD","BK1191","LU0661504455.SGD","LU2637428348.USD","BK1593","IE00BVYPNQ40.USD","LU0553294199.USD","LU0545039389.USD","LU2488822045.USD","SG9999015952.SGD","IE00BVYPNP33.GBP","LU2346227817.USD","BK4588","LU0949170772.SGD","SG9999015986.USD"],"gpt_icon":0},{"id":"1121343937","title":"CMS (00867) Self-Developed Innovative Drug CMS-D017 Capsule Receives Clinical Trial Approval Notice for Complement-Mediated Kidney Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=1121343937","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121343937?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:06","pubTimestamp":1770123960,"startTime":"0","endTime":"0","summary":"On February 3, 2026, CMS (00867) announced that its self-developed innovative drug, the CMS-D017 capsule, has received a drug clinical trial approval notice issued by the National Medical Products...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IE00BVYPNQ40.USD","SG9999015978.USD","LU2500361329.USD","IE00BVYPNP33.GBP","00867","LU0553294199.USD","SG9999015945.SGD","IE00BMCWC346.EUR","LU0661504455.SGD","LU1003077747.HKD","IE00BGHQDM52.EUR","BK4208","LU0545039389.USD","LU2488822045.USD","BK4588","SG9999015986.USD","LU0949170772.SGD","SG9999015952.SGD","159992","IE00BYV24P56.USD","BK1574","BK1191","CMS","LU2346227817.USD","SG9999004220.SGD","LU1894683264.USD","BK1593","BK4585","LU0738911758.USD","LU1894683348.USD","LU2637428348.USD","06978"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}